Over the last two years, the surging demand for GLP-1 receptor agonists such as semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound™) has created both clinical and supply chain challenges. While these products were on the U.S. Food and Drug Administration’s (“FDA”) drug shortage list, 503B outsourcing facilities and 503A compounding pharmacies stepped in to fill the gap, compounding patient-specific or office-use formulations to meet patient needs.
When the FDA later removed semaglutide and tirzepatide from the shortage list, many 503B outsourcing facilities ceased compounding in accordance with court orders from the Northern District of Texas. However, a number of 503A pharmacies continued compounding GLP-1 products, taking care to demonstrate that their preparations were not “essentially a copy” of the FDA-approved versions.
Today, a new trend is emerging: several 503B outsourcing facilities are contemplating or have already resumed the production of compounding GLP-1 products containing tirzepatide or semaglutide. The permissibility of these activities, and the relative risk on different stakeholders, may depend on a variety of factors, including the composition of the products and the circumstances of how they are produced and dispensed/delivered to patients.
This article outlines the legal and regulatory framework allowing for compounding by 503B outsourcing facilities, the risks faced by 503B outsourcing facilities compounding these products, and the potential exposure for other stakeholders such as pharmacies receiving product from 503B outsourcing facilities for subsequent patient dispensing.
Legal Framework for 503B Compounding of GLP-1s
Under Section 503B of the Federal Food, Drug, and Cosmetic Act (“FDCA”), outsourcing facilities may compound medications without patient-specific prescriptions if they comply with current good manufacturing practice (cGMP) standards and other requirements. Importantly, 503Bs may only compound products that are not “essentially copies” of FDA-approved drugs unless the approved drug appears on FDA’s shortage list.
This framework creates significant limitations for outsourcing facilities seeking to reinitiate semaglutide or tirzepatide production.
- Bulk Ingredient Restrictions: Neither semaglutide nor tirzepatide is included on the list of bulk active pharmaceutical ingredients (APIs) capable of being compounded by a 503B facility, an outsourcing facility would otherwise be limited in its ability to utilize API versions of these products in compounding unless the products were deemed to be in shortage. Since the FDA has removed semaglutide and tirzepatide from its shortage list, a 503B facility generally cannot lawfully compound these drugs in standard formulations.
- Essentially a Copy Limitations: Even if aside from the API limitations, Section 503B places limitations on outsourcing facilities compounding essentially a copy of an FDA approved drug. The FDA defines an “essentially a copy” compounded drug as one that is identical or nearly identical to a commercially available drug. Thus, demonstrating a “clinically significant difference” (e.g., preservative-free, alternative dosage form, or combination with other active ingredients) is required to justify compounding.
Risks for 503B Outsourcing Facilities
In the face of these risks, several 503B outsourcing facilities have explored creative ways to resume compounding GLP-1 products. Outsourcing facilities considering re-entry into the GLP-1 space must weigh several risks:
- FDA Enforcement: FDA has already issued warning letters and public statements signaling heightened scrutiny over compounded GLP-1s. Additional warning letters regarding advertising were just issued earlier this month. Restarting compounding without a valid “shortage” justification or clear differentiation from the approved drug may invite enforcement action.
- State Board Oversight: State Boards of Pharmacy may adopt their own interpretations of “essentially a copy,” and many have taken active steps to discipline pharmacies and outsourcing facilities compounding GLP-1s without clear clinical justification.
- Manufacturer Pressure: Pharmaceutical manufacturers have aggressively sought to limit off-label and compounded distribution of GLP-1s, including through civil litigation, cease-and-desist letters, and collaboration with regulators.
The 503B-to-503A Fulfillment Pathway
One concept that has been explored by 503B facilities – both before and after the ending of the shortage – is the supply of compounded product by a 503B facility to a 503A pharmacy, for subsequent dispensing to a patient.
Following FDA’s Guidance: Wholesaling Under Section 503B of the Federal Food, Drug, and Cosmetic Act (June 2023), many 503B outsourcing facilities historically supplied compounded GLP-1s to 503A pharmacies, which then dispensed the products to patients under patient-specific prescriptions. While this Guidance suggested that such activities would to be considered prohibited wholesaling or redistribution by 503B facilities, this Guidance did not indicate what role 503B facilities would be occupying when they compounded the products. Further, this Guidance did not address how this interplayed with the concept of “anticipatory compounding” by 503Bs for 503A, which the FDA has previously suggested can be done in a “limited amount.”
Ultimately, this pathway carries its own risks. First, while outsourcing facilities may argue that supplying to 503A pharmacies mitigates exposure by shifting prescription-level responsibility, FDA has not explicitly sanctioned 503B-to-503A fulfillment for drugs no longer on shortage. Second, because the regulatory pathway to accept inventory from a 503B facility is vague (even without considering the limitations on GLP-1 compounding), pharmacies accepting GLP-1 inventory from 503Bs may themselves face state board scrutiny or FDA action if the underlying compounded product is deemed unlawful. Finally, with renewed focus on supply chain integrity, both 503Bs and 503As must maintain robust documentation to demonstrate compliance with DSCSA requirements, prescription validity, and non-duplication with FDA-approved therapies.
Practical Takeaways for 503Bs and 503As
For 503B outsourcing facilities and 503A compounding pharmacies considering participation in this market, the following considerations are critical:
- Evaluate Clinical Justification: Document and substantiate any clinically significant differences (e.g., allergen-free formulation, alternative dosage strengths) to defend against “essentially a copy” allegations.
- Assess Risk Tolerance: Recognize that FDA, state boards, and manufacturers have all signaled active interest in restricting compounded GLP-1s. Enforcement risk is not theoretical.
- Structure 503B-to-503A Relationships Carefully: Written agreements, dispensing protocols, and inventory controls should clarify responsibilities and mitigate regulatory exposure.
- Monitor Regulatory Developments: The GLP-1 space is evolving rapidly, and FDA may issue further clarifications or enforcement actions impacting both 503Bs and 503As.
- Take Affirmative Actions: Several stakeholders – including 503B outsourcing facilities and 503A compounding pharmacies – have taken proactive and direct actions against regulators and manufacturers relative to GLP-1 compounding limitations. In addition to OFA’s suit against the FDA, a bulk API supplier recently sued the California Board of Pharmacy challenging impending compounding regulations and multiple 503B outsourcing facilities have affirmative sought to challenge Eli Lilly’s tirzepatide patent.
Conclusion
The renewed interest among outsourcing facilities in compounding semaglutide and tirzepatide highlights the ongoing demand for GLP-1 therapies and the complex interplay between patient access and regulatory compliance. While some 503B facilities may explore pathways to re-enter this market, the risks from FDA, state boards, and manufacturers are substantial. Both 503Bs and 503As should proceed cautiously, seek legal counsel, and develop robust compliance strategies before engaging in GLP-1 compounding. If you have questions or need assistance, contact Frier Levitt to speak to one of our knowledgeable attorneys.
Frier Levitt provides strategic, industry-focused legal counsel tailored to your needs. Contact our team today to learn how we can help you.
